Latest / Interprofessional Critical Care Network (ICCN) Podcast / Stop Treating Vasopressors Like Blood Pressure Glue
Transcript
- 0:00SPEAKER_01: What if I told you that in intensive care units right now,
- 0:04the very medication doctors are using to make a patient's vital
- 0:08signs look
- 0:10absolutely perfect on a monitor might actually be starving
- 0:13their organs of oxygen.
- 0:15SPEAKER_00: It sounds like a complete contradiction, I know.
- 0:18SPEAKER_00: You walk into an ICU room,
- 0:19SPEAKER_00: the numbers on the screen are glowing green,
- 0:21SPEAKER_00: everything looks totally stable,
- 0:23SPEAKER_00: and yet the patient is quietly deteriorating right in front of you.
- 0:28SPEAKER_01: Welcome to this deep dive.
- 0:29Today we are going to fundamentally change how you think about
- 0:33life support,
- 0:35SPEAKER_01: critical care medicine,
- 0:36SPEAKER_01: and really just the blind trust we put in medical technology.
- 0:39SPEAKER_00: Exactly.
- 0:39SPEAKER_01: Because,
- 0:40SPEAKER_01: I mean,
- 0:40SPEAKER_01: if someone you love is in the hospital,
- 0:41you naturally assume that fixing the numbers on the machines
- 0:44means fixing the
- 0:45SPEAKER_01: patient.
- 0:45SPEAKER_00: Definitely so, yeah.
- 0:46But we are going to explore why treating these powerful
- 0:50medications as if they are
- 0:51just like blood pressure glue is one of the most dangerous
- 0:55traps in modern
- 0:55SPEAKER_01: medicine.
- 0:56And the best part is you really don't need a medical degree to
- 1:00follow this.
- 1:01SPEAKER_00: At its core, this is a fascinating lesson in systems thinking.
- 1:05SPEAKER_00: It's about unintended consequences,
- 1:07SPEAKER_00: the geography of the human body,
- 1:09and the massive difference between treating a pixelated number
- 1:12on a screen versus
- 1:14SPEAKER_00: treating a complex human being.
- 1:16SPEAKER_01: Okay, let's unpack this.
- 1:17Our guiding source today is a really eye-opening piece
- 1:20published on May 6,
- 1:222026.
- 1:23SPEAKER_01: Right.
- 1:23SPEAKER_01: It's from the ICCN Substack,
- 1:25SPEAKER_01: written by Javier Amador-Castaneda,
- 1:28and it is titled Vasoactive Science Beyond the Blood Pressure
- 1:32Glue Reflect
- 1:33SPEAKER_01: Sterning.
- 1:33SPEAKER_00: It's such a great title.
- 1:35SPEAKER_01: It really is.
- 1:36SPEAKER_01: And that phrase,
- 1:37SPEAKER_01: blood pressure glue,
- 1:38SPEAKER_01: it's so vivid,
- 1:39it perfectly describes the terrifying mistake Amador-Castaneda
- 1:42is calling out.
- 1:43SPEAKER_00: Right.
- 1:43SPEAKER_00: This habit of treating these powerful ICU drugs.
- 1:46SPEAKER_00: They're called vasopressors.
- 1:47SPEAKER_00: Yeah.
- 1:47As if they're just like magical glue you inject to hold a
- 1:50patient's collapsing
- 1:51SPEAKER_00: blood pressure together.
- 1:52SPEAKER_01: Yeah.
- 1:52And the author uses a specific term for the mechanics of this
- 1:55trap,
- 1:56right?
- 1:56SPEAKER_00: He does.
- 1:56SPEAKER_00: He calls it knob turning.
- 1:57SPEAKER_01: Knob turning.
- 1:58SPEAKER_01: Okay.
- 1:58SPEAKER_01: So what does that actually look like?
- 2:00SPEAKER_00: Well, to understand it, just picture the chaotic environment of an ICU.
- 2:04SPEAKER_00: You have a patient in a state of shock.
- 2:06SPEAKER_00: The monitor alarms.
- 2:08SPEAKER_00: It says their mean arterial pressure, their MAP is, let's say, 58.
- 2:12SPEAKER_00: Okay.
- 2:13SPEAKER_00: Now,
- 2:13SPEAKER_00: the 2026 Surviving Sepsis Campaign Guidelines,
- 2:17SPEAKER_00: they recommend an initial MAP target of 65 millimeters of mercury.
- 2:22SPEAKER_00: So,
- 2:22SPEAKER_00: the nurse or the doctor looks at the 58,
- 2:25SPEAKER_00: reaches for the IV pump,
- 2:27SPEAKER_00: and just turns the medication knob up.
- 2:29SPEAKER_01: And then I'm guessing a few minutes later, the MAP hits 72.
- 2:33SPEAKER_00: Presto, job done, right?
- 2:34SPEAKER_01: Right.
- 2:34SPEAKER_00: So you turn the knob down a bit,
- 2:36SPEAKER_00: the pressure drops back to 60,
- 2:37SPEAKER_00: you turn it back up,
- 2:38SPEAKER_00: maybe you hang another bag of medication.
- 2:41SPEAKER_00: You are basically locked in this endless cycle of chasing a number.
- 2:45It's honestly like treating the dashboard of your car instead
- 2:47of the engine.
- 2:48SPEAKER_00: That's exactly it.
- 2:48SPEAKER_01: If the check engine light comes on,
- 2:50SPEAKER_01: you don't just,
- 2:51SPEAKER_01: you know,
- 2:51SPEAKER_01: hack the computer to turn the light off and say,
- 2:53SPEAKER_01: hey,
- 2:53SPEAKER_01: the car is fixed.
- 2:54SPEAKER_00: Right.
- 2:55SPEAKER_01: But wait,
- 2:55SPEAKER_01: I want to push back on this early on because,
- 2:57SPEAKER_01: I mean,
- 2:57SPEAKER_01: the guidelines exist for a reason.
- 2:59SPEAKER_01: You mentioned the 2026 sepsis guidelines say to hit an MAP of 65.
- 3:04SPEAKER_00: They do.
- 3:04SPEAKER_01: They even say to start these drugs peripherally,
- 3:07SPEAKER_01: like,
- 3:07through a regular 5V in the arm so you don't waste precious
- 3:11time putting a big
- 3:11SPEAKER_01: central line into the neck.
- 3:13SPEAKER_00: Correct.
- 3:14SPEAKER_01: So if the nurse turns up the drug and hits 65 quickly,
- 3:17SPEAKER_01: aren't we doing exactly what the science says?
- 3:20SPEAKER_01: Doesn't getting that pressure up early mean we save them?
- 3:23SPEAKER_00: That is the exact illusion this article dismantles,
- 3:27SPEAKER_00: to see why we have to look at the body's geography.
- 3:30SPEAKER_01: Okay, lay it out for me.
- 3:31SPEAKER_00: Think of the circulatory system really simply.
- 3:34You have pump,
- 3:35which is the heart,
- 3:36and you have the pipes,
- 3:37which are the blood vessels.
- 3:38SPEAKER_01: Gotcha.
- 3:38SPEAKER_00: When a patient is in severe shock, those pipes lose their tone.
- 3:42SPEAKER_00: They become floppy.
- 3:44SPEAKER_00: So the medical team reaches for an anchor drug to tighten them back up.
- 3:47SPEAKER_00: And the absolute gold standard anchor is norepinephrine.
- 3:51SPEAKER_01: Which is a pretty heavy-duty vasopressor.
- 3:54SPEAKER_00: It is.
- 3:54SPEAKER_00: It works primarily by targeting alpha-1 receptors in the body.
- 3:58If you imagine those receptors as little switches on the walls
- 4:01of the pipes,
- 4:02SPEAKER_00: hitting them causes the smooth muscle to squeeze.
- 4:04SPEAKER_01: So it increases the vascular tone?
- 4:07SPEAKER_00: Exactly.
- 4:08SPEAKER_00: Norepinephrine also has a little bit of beta-1 activity,
- 4:10SPEAKER_00: which hits switches on the heart itself,
- 4:12SPEAKER_00: giving the pump a tiny bit of extra squeezing power too.
- 4:16And the data on why norepinephrine is the go-to anchor is
- 4:19actually pretty stark.
- 4:21The author brings up this major historical study called the
- 4:23Esokipu trial.
- 4:25SPEAKER_00: Oh, yeah.
- 4:25SPEAKER_00: That was a huge one.
- 4:26SPEAKER_01: It compared norepinephrine to an older drug called dopamine.
- 4:30SPEAKER_01: Now,
- 4:31the overall mortality rates weren't statistically different
- 4:33between the two,
- 4:34SPEAKER_01: but the side effects were night and day.
- 4:36SPEAKER_00: Completely different.
- 4:37Like dopamine caused massive,
- 4:39dangerous heart arrhythmias in 24.1% of patients.
- 4:45SPEAKER_01: Compared to just 12.4% for norepinephrine, it literally doubled the risk.
- 4:49Which is exactly why dopamine was largely dethroned and
- 4:52norepinephrine became the anchor.
- 4:54SPEAKER_00: But let's go back to your question.
- 4:55SPEAKER_00: You hit a BAMAP of 65 with norepinephrine.
- 4:58SPEAKER_00: Why haven't you saved the patient?
- 5:00SPEAKER_01: Right.
- 5:00SPEAKER_01: Why?
- 5:01SPEAKER_00: Because pressure does not equal flow.
- 5:03SPEAKER_01: Break that down for me.
- 5:04SPEAKER_01: What do you mean?
- 5:05Well,
- 5:05the goal of the circulatory system isn't just to create
- 5:07pressure in a vacuum,
- 5:09right?
- 5:09SPEAKER_00: It's to deliver actual oxygen to the tissues.
- 5:12If you just keep turning the norpinephrine knob higher and
- 5:16higher to force the
- 5:17SPEAKER_00: monitor to read 65,
- 5:20SPEAKER_00: you are hitting those alpha-1 switches so hard that the pipes clamp down
- 5:24SPEAKER_00: completely.
- 5:25SPEAKER_00: The blood vessels become incredibly narrow.
- 5:27SPEAKER_01: So the pressure behind the clamp goes way up.
- 5:29SPEAKER_00: But nothing is flowing through.
- 5:31SPEAKER_01: Oh, wow.
- 5:32SPEAKER_00: The monitor looks beautiful,
- 5:33SPEAKER_00: but if you actually look at the human being in the bed,
- 5:36SPEAKER_00: their toes and fingers are turning cold and blue.
- 5:40SPEAKER_01: Oh, that's terrifying.
- 5:41Their urine output drops to zero because blood isn't reaching
- 5:44the kidneys.
- 5:46SPEAKER_00: The lactate levels in their blood are rising rapidly,
- 5:48SPEAKER_00: which is a sign their cells are literally choking.
- 5:51SPEAKER_01: So you haven't resuscitated them at all?
- 5:53SPEAKER_00: No,
- 5:53you've just strangled their microcirculation just to make a
- 5:56computer screen spit
- 5:56SPEAKER_00: out a passing grade.
- 5:58SPEAKER_01: That is wild.
- 5:59SPEAKER_01: You fix the number while actively starving the organs.
- 6:03So pushing this anchor drug higher and higher eventually just
- 6:07becomes toxic.
- 6:07SPEAKER_01: The anchor starts dragging you under.
- 6:10SPEAKER_01: What happens then?
- 6:11SPEAKER_01: Because eventually the patient's body must just,
- 6:13SPEAKER_01: I don't know,
- 6:13SPEAKER_01: stop responding to all that alpha-1 squeezing,
- 6:15SPEAKER_01: right?
- 6:16SPEAKER_00: Wow.
- 6:16SPEAKER_00: Wow.
- 6:39Which brings us to the second drug the author explores,
- 6:42which is vasopressin.
- 6:44So if the alpha-1 switches are broken or maxed out,
- 6:47how does vasopressin work?
- 6:48It targets something completely different V1 receptors on the
- 6:51vascular smooth muzzle.
- 6:53SPEAKER_00: And Amador-Castaneda highlights a really vital concept here.
- 6:57SPEAKER_00: Vasopressin is what we call catecholamine sparing.
- 7:00SPEAKER_01: Okay, let's translate that.
- 7:01SPEAKER_01: Catecholamines are things like adrenaline,
- 7:03SPEAKER_01: those harsh stress-inducing fight-or-flight chemicals,
- 7:06SPEAKER_01: right?
- 7:06SPEAKER_00: Exactly.
- 7:07SPEAKER_00: Norepinephrine is a catecholamine.
- 7:09SPEAKER_00: Pumping massive doses of it causes profound toxic stress to the body.
- 7:13SPEAKER_00: Vasopressin provides non-adrenergic vasoconstriction.
- 7:16SPEAKER_01: Meaning it squeezes the pipes without the adrenaline.
- 7:19Yes,
- 7:19it squeezes the pipes,
- 7:21but it doesn't use the adrenaline system to do it.
- 7:23SPEAKER_00: It's a much smoother, way less toxic way to restore vascular tone.
- 7:28SPEAKER_01: It's almost like your primary electrical circuit is overheating,
- 7:31so you flip a breaker and run the power through a completely
- 7:34different cooler
- 7:35SPEAKER_01: circuit.
- 7:36SPEAKER_00: That's a great way to picture it.
- 7:37SPEAKER_00: And the guidelines suggest making this pivot early.
- 7:40SPEAKER_00: Practically speaking,
- 7:41SPEAKER_00: when the norepinephrine dose is creeping up,
- 7:44SPEAKER_00: usually around the 0.25 to 0.5 micrograms per kilogram per minute range,
- 7:49SPEAKER_00: you shouldn't wait for it to max out.
- 7:50SPEAKER_01: You just add the vasopressant.
- 7:52SPEAKER_01: And the medical trials absolutely back this up.
- 7:55The article cites two massive ones,
- 7:57the VISITEE trial and the VANISH trial.
- 7:59SPEAKER_01: We don't need to get bogged down on the decimal points,
- 8:01SPEAKER_01: but the magnitude of the results is huge.
- 8:04SPEAKER_01: Like,
- 8:04SPEAKER_01: in less severe shock,
- 8:06adding vasopressin lowered the 28-day mortality rate down to
- 8:1026.5% versus 35.7%.
- 8:13SPEAKER_00: It's a huge difference.
- 8:14SPEAKER_01: And even more impressively,
- 8:15it drastically reduced the number of patients who suffered
- 8:18kidney failure and ended
- 8:19SPEAKER_01: up needing dialysis.
- 8:20SPEAKER_01: I think the rate dropped from 35.3% down to 25.4%.
- 8:24SPEAKER_00: Yeah, because it's a different pathway.
- 8:27It protects the flow to those delicate renal organs while still
- 8:31keeping the pressure up.
- 8:32SPEAKER_01: So here's a fascinating twist, though.
- 8:34If adding vasopressin early is so protective,
- 8:37why are doctors sometimes slow to do it?
- 8:39SPEAKER_01: Because the article brings up this 2025 AI study
- 8:43SPEAKER_01: The OVISS Reinforcement Learning Study.
- 8:46Researchers basically fed thousands of ICU patient files into
- 8:50an artificial
- 8:50SPEAKER_01: intelligence algorithm to see how it would manage the drugs.
- 8:54SPEAKER_00: Right.
- 8:54And the AI suggested starting vasopressin way earlier than
- 8:57human doctors usually do.
- 8:59SPEAKER_00: It did.
- 8:59The AI looked at the patterns and essentially said,
- 9:03hey,
- 9:03the alpha-1 pathway is failing.
- 9:05SPEAKER_00: Stop wasting time and pull the V1 lever.
- 9:07SPEAKER_00: Wow.
- 9:08SPEAKER_00: But Amador-Castaneda is very deliberate about how we interpret this.
- 9:12SPEAKER_00: The AI study is an observational signal.
- 9:14SPEAKER_00: It's like a mirror showing us our own hesitations.
- 9:16SPEAKER_00: Right.
- 9:17What's fascinating here is that it is absolutely not an excuse
- 9:21to hook the IV pumps
- 9:22SPEAKER_00: up to a closed-loop AI and leave the room.
- 9:24SPEAKER_01: Because the AI doesn't see the patient's cold toes?
- 9:27SPEAKER_01: Okay, so we've mapped out the pipes.
- 9:29We've got our anchor norepinephrine and our backup vasopressin
- 9:33fixing the tone of
- 9:34SPEAKER_01: the blood vessels.
- 9:35SPEAKER_01: But what if the pipes aren't the main problem anymore?
- 9:38What happens when the shock is so deep that the heart itself,
- 9:41the pump,
- 9:42starts to fail?
- 9:43SPEAKER_00: That's when you have to call in the heavy hitters.
- 9:45SPEAKER_00: And the loudest of those is epinephrine.
- 9:49SPEAKER_01: Okay, let's talk about epinephrine.
- 9:51The author lays out its receptor profile and it basically hits
- 9:55everything on the
- 9:55SPEAKER_01: board,
- 9:55SPEAKER_01: doesn't it?
- 9:56SPEAKER_01: Pretty much.
- 9:56SPEAKER_01: Alpha-1 to squeeze the pipes, beta-1 to squeeze the heart, and beta-2.
- 10:00SPEAKER_01: What exactly does beta-2 do?
- 10:02SPEAKER_00: Well,
- 10:02SPEAKER_00: beta-2 receptors cause the smooth muscles to relax,
- 10:06SPEAKER_00: but more importantly for this discussion,
- 10:08SPEAKER_00: hitting them triggers a massive metabolic response in the body.
- 10:11SPEAKER_00: Epinephrine raises blood pressure,
- 10:13SPEAKER_00: it raises heart rate,
- 10:14SPEAKER_00: it forces blood flow,
- 10:16SPEAKER_00: but it also causes lactate levels in the blood to just skyrocket.
- 10:20SPEAKER_01: Wait, but earlier you said rising lactate was the ultimate red flag.
- 10:23SPEAKER_01: You said it means the cells are choking and dying.
- 10:26SPEAKER_01: So if a doctor gives epinephrine and sees the lactate spike...
- 10:29How do they know if the drug is actually working or if the
- 10:32patient is just dying faster?
- 10:34SPEAKER_00: That is the genius of understanding the physiology here.
- 10:36SPEAKER_01: Yeah.
- 10:37SPEAKER_00: Ebinephrine causes something called beta 2 mediated glycolysis.
- 10:41SPEAKER_00: Let's use an analogy.
- 10:43SPEAKER_00: Imagine you have a car engine.
- 10:44SPEAKER_01: Okay.
- 10:45SPEAKER_00: Oh, I see.
- 11:05SPEAKER_00: The engine isn't braking, it's just in massive overdrive.
- 11:09SPEAKER_00: That epinephrine-induced lactate spike is just metabolic exhaust.
- 11:13SPEAKER_00: It doesn't automatically mean the tissues are dying.
- 11:15SPEAKER_01: But it totally clouds the picture.
- 11:17SPEAKER_01: It's making so much smoke you can't read the dashboard anymore.
- 11:19SPEAKER_00: Which makes managing the patient infinitely harder.
- 11:22SPEAKER_00: You have to rely on other clues,
- 11:24SPEAKER_00: like urine output and skin temperature,
- 11:26SPEAKER_00: to know if they're actually getting better.
- 11:28SPEAKER_01: So if epinephrine is this, like, loud, messy, nitrous-injected option,
- 11:34SPEAKER_01: What's the alternative when you're really desperate?
- 11:36SPEAKER_01: The source brings up an escape hatch drug called angiotensin II.
- 11:40Angiotensin II is one of the most fascinating developments in
- 11:44critical care.
- 11:45SPEAKER_00: It hits AT1 receptors, which are part of the renin-angiotensin pathway.
- 11:48We are now talking about a third entirely distinct biological
- 11:53lever to pull.
- 11:54SPEAKER_01: And the trial data here, the ATHOS-3 trial, is mind-blowing.
- 11:57SPEAKER_01: They tested angiotensin II on patients in refractory shock.
- 12:01SPEAKER_00: The sickest of the sick.
- 12:02SPEAKER_01: Literally the absolute sickest.
- 12:03People who were completely maxed out on everything else and
- 12:06still crashing.
- 12:07SPEAKER_01: Angiotensin II produced a massive blood pressure response at three hours.
- 12:11SPEAKER_01: We're talking a 69.9% success rate compared to just 23.4% for a placebo.
- 12:17SPEAKER_00: Yeah, the power of the drug is undeniable.
- 12:19SPEAKER_01: Okay, but genuine question here.
- 12:20If I'm a patient in shock and you have a drug that has a 69.9%
- 12:24success rate at
- 12:25SPEAKER_01: fixing my blood pressure,
- 12:27SPEAKER_01: Why on earth is it the escape hatch?
- 12:28SPEAKER_01: Right.
- 12:29I mean,
- 12:29why isn't this the very first thing you reach for when I roll
- 12:32through the ICU doors?
- 12:33SPEAKER_00: It's a great question, and it brings us right back to the central theme.
- 12:36SPEAKER_00: Treating the whole physiology, not just a number.
- 12:40Angiotens II is incredibly powerful,
- 12:43but it really only fixes one specific problem,
- 12:46vasobligia.
- 12:47SPEAKER_01: Which is what?
- 12:48SPEAKER_00: Vasoplygia is the complete catastrophic loss of vascular tone.
- 12:54SPEAKER_00: The pipes are entirely dilated and paralyzed.
- 12:57SPEAKER_00: Angiotensin II will aggressively squeeze them shut.
- 13:00SPEAKER_01: Okay.
- 13:00SPEAKER_00: But what if your blood pressure is low for a different reason?
- 13:03SPEAKER_00: What if your heart is severely failing as a pump?
- 13:06Or what if you are bleeding internally and there just isn't
- 13:09enough fluid in the pipes?
- 13:10Oh,
- 13:10just the pump is weak and I give you a drug that violently
- 13:13squeezes the pipe.
- 13:14SPEAKER_00: You've just forced a failing heart to push against a concrete wall.
- 13:18The blood pressure number on the monitor will suddenly look
- 13:20absolutely gorgeous,
- 13:22right up until the heart completely gives out and the
- 13:24circulation collapses.
- 13:25Wow,
- 13:25you've literally engineered their demise while thinking you
- 13:28cured them.
- 13:29SPEAKER_00: Exactly.
- 13:30This is why the 2026 sepsis guidelines do not make angiotensin
- 13:34II a default step.
- 13:35SPEAKER_00: It's a precision tool.
- 13:37It requires incredibly strict patient selection to ensure you
- 13:40are treating pure
- 13:42SPEAKER_00: vasoplegia,
- 13:43SPEAKER_00: not a failing heart.
- 13:44SPEAKER_01: That makes sense.
- 13:45SPEAKER_00: Plus, it's wildly expensive and just not available everywhere.
- 13:49SPEAKER_01: Okay, so we've built the modern receptor map.
- 13:51SPEAKER_01: We know the pathways, alpha-1, beta-1, V1, AT1.
- 13:56But Amador-Castaneda spent a significant portion of this
- 13:58article warning us about
- 14:00SPEAKER_01: the ghosts of the past.
- 14:01SPEAKER_00: The old favorites.
- 14:02SPEAKER_01: Yeah.
- 14:02SPEAKER_01: There are two older drugs that still linger in hospital cabinets,
- 14:06SPEAKER_01: and he argues they teach doctors and nurses incredibly dangerous habits.
- 14:10SPEAKER_01: Let's start with phenylophrine.
- 14:12SPEAKER_00: Phenylophrine is the classic example of what we were just talking about.
- 14:14SPEAKER_00: It is a pure alpha-1 agonist.
- 14:16SPEAKER_01: Pure alpha-1.
- 14:17SPEAKER_01: So all squeeze on the pipes, zero help for the pump.
- 14:19SPEAKER_00: Precisely.
- 14:20Remember how norepinephrine has a little bit of beta-1 activity
- 14:23to help the heart
- 14:23SPEAKER_00: pump against the newly tightened vessels?
- 14:25SPEAKER_01: Yeah.
- 14:25SPEAKER_00: Phenylophrine doesn't have that.
- 14:26SPEAKER_00: It just clamps the vessels down.
- 14:28SPEAKER_00: In medical terms,
- 14:29SPEAKER_00: it massively increases the afterload,
- 14:32SPEAKER_00: which is the resistance the heart has to overcome.
- 14:34SPEAKER_01: It's the brick wall.
- 14:35SPEAKER_00: It's building a brick wall in front of a struggling heart.
- 14:38SPEAKER_00: And if the heart can't push through it,
- 14:40SPEAKER_00: the patient's actual cardiac output,
- 14:43SPEAKER_00: the amount of blood flowing to the organs,
- 14:45SPEAKER_00: plummets.
- 14:45But the blood pressure number on the monitor goes up because
- 14:49the pipes are tight.
- 14:50SPEAKER_00: And that's exactly why it's a dangerous habit.
- 14:53It rewards the clinician with a beautiful MAP of 65 while
- 14:57actively starving the
- 14:58SPEAKER_00: patient of blood flow.
- 14:59SPEAKER_01: That is deeply unsettling.
- 15:01SPEAKER_01: But the second drug he targets is even more notorious, I think.
- 15:04SPEAKER_01: Dopamine.
- 15:05SPEAKER_00: Oh, dopamine.
- 15:06We already established from the SOP2 trial that dopamine
- 15:09practically doubles the
- 15:10SPEAKER_01: rate of heart arrhythmias compared to norepinephrine.
- 15:13But the source talks about this stubborn myth that kept
- 15:16dopamine in hospitals for decades.
- 15:18SPEAKER_01: The renal dose dopamine theory.
- 15:21SPEAKER_00: Right.
- 15:22For a long time,
- 15:23medical schools taught this beautifully neat,
- 15:26elegant theory.
- 15:27SPEAKER_00: They said that if you give dopamine in very,
- 15:29SPEAKER_00: very low doses,
- 15:30SPEAKER_00: it doesn't hit the heart or the main vessels.
- 15:33SPEAKER_00: Instead,
- 15:33SPEAKER_00: it specifically targets receptors in the kidneys,
- 15:36SPEAKER_00: dilating those vessels and protecting renal function.
- 15:38SPEAKER_01: So like a magic bullet to save the kidneys during shock?
- 15:41SPEAKER_00: It sounded perfect?
- 15:43SPEAKER_01: Yeah!
- 15:44SPEAKER_00: The problem.
- 15:44SPEAKER_00: It just wasn't true.
- 15:46A massive study called the ANZICS trial finally put it to the
- 15:50test and definitively
- 15:51proved that low-dose dopamine does zero to protect renal
- 15:55function in critically ill
- 15:56SPEAKER_00: patients.
- 15:57SPEAKER_00: It was a complete illusion.
- 15:58Okay,
- 15:58I have to stop you there because this is where the medical
- 16:00inertia drives me crazy.
- 16:01SPEAKER_01: The ANZ ICS trial proved it doesn't save the kidneys.
- 16:04SPEAKER_01: The SOAP2 trial proved it damages the heart.
- 16:08SPEAKER_01: Why is this drug even a temptation anymore?
- 16:11SPEAKER_01: Why hasn't it been banned from the ICO entirely?
- 16:14SPEAKER_00: Because human nature loves a simple story.
- 16:18It is incredibly tempting for a stressed out medical provider
- 16:21to rely on a neat
- 16:22SPEAKER_00: dose dependent narrative.
- 16:24Low dose for the kidneys,
- 16:25medium dose for the heart,
- 16:26high dose for blood pressure.
- 16:28SPEAKER_00: Gives a false sense of control.
- 16:30SPEAKER_00: But human physiology doesn't care about our simple textbook stories.
- 16:34SPEAKER_00: When you rely on myths at the bedside, patients get hurt.
- 16:37SPEAKER_01: Which brings us to the most crucial pivot of this entire deep dive.
- 16:40SPEAKER_01: Amador-Castaneda argues that you can memorize every single receptor.
- 16:44SPEAKER_01: You can understand every trial.
- 16:46But all of this science is completely useless if the human
- 16:49beings standing around
- 16:50SPEAKER_01: the patient's bed aren't communicating.
- 16:52SPEAKER_00: Because true hemodynamic management isn't a solo act.
- 16:55SPEAKER_00: It is a symphony.
- 16:57And the entire interprofessional team has to play together to
- 16:59make it work.
- 17:01SPEAKER_01: Let's look at the orchestra.
- 17:02SPEAKER_01: You have the nurse.
- 17:03SPEAKER_01: In a world of AI and monitors, why is the nurse so vital?
- 17:08SPEAKER_00: The nurse is the front line of reality.
- 17:10SPEAKER_00: They are the ones physically touching the patient.
- 17:12SPEAKER_00: They see the skin modeling,
- 17:14SPEAKER_00: you know,
- 17:14SPEAKER_00: those purple blotchy patches that mean blood isn't flowing.
- 17:17SPEAKER_01: Right.
- 17:17SPEAKER_00: They check the capillary refill by pressing on a fingernail.
- 17:21SPEAKER_00: They measure the urine output minute by minute.
- 17:23The nurse is the safety net that prevents the resuscitation
- 17:26from becoming purely mechanical.
- 17:29SPEAKER_00: If the computer says the patient is fine,
- 17:31SPEAKER_00: but the nurse says the patient's legs are turning ice cold,
- 17:34SPEAKER_00: you listen to the nurse.
- 17:35SPEAKER_01: The human over the machine.
- 17:36SPEAKER_01: Then you have the respiratory therapist, the RT.
- 17:39SPEAKER_01: Why do they care about blood pressure meds?
- 17:40SPEAKER_01: They manage the ventilators, right?
- 17:42SPEAKER_00: They do.
- 17:43SPEAKER_00: But the heart and the lungs share the same crowded box, the chest cavity.
- 17:47SPEAKER_00: The RT is trained to spot heart-lung interactions.
- 17:50SPEAKER_01: How does that work?
- 17:52SPEAKER_00: Well,
- 17:52let's say an RT increases the pressure on a ventilator to help
- 17:55a patient breathe,
- 17:56SPEAKER_00: and suddenly the patient's blood pressure crashes,
- 17:59SPEAKER_00: requiring double the vasopressors.
- 18:02The RT recognizes that the mechanical lung pressure is
- 18:05physically squishing the
- 18:06SPEAKER_00: heart,
- 18:06SPEAKER_00: preventing it from filling with blood.
- 18:08SPEAKER_01: Oh, wow.
- 18:08SPEAKER_00: The patient doesn't need more drugs.
- 18:10SPEAKER_00: They need the ventilator adjusted.
- 18:12SPEAKER_01: It's all connected.
- 18:13SPEAKER_01: Then we have the pharmacist.
- 18:15SPEAKER_01: In this orchestra, they are the receptor strategists.
- 18:18SPEAKER_00: They are the guardrails.
- 18:19SPEAKER_00: A good ICU pharmacist is constantly looking at the whole picture.
- 18:24SPEAKER_00: If the doctor orders epinephrine,
- 18:26SPEAKER_00: the pharmacist is the one warning the team,
- 18:28SPEAKER_00: hey,
- 18:28SPEAKER_00: remember,
- 18:29SPEAKER_00: this is going to cause a massive lactate spike in about an hour.
- 18:32SPEAKER_00: That's just the engine exhaust.
- 18:34SPEAKER_00: Don't panic and think the patient is dying.
- 18:36They prevent the knee-jerk reactions,
- 18:38and then the physician or the advanced practice provider
- 18:41SPEAKER_00: Their job isn't just to blindly write the order for the drug.
- 18:44SPEAKER_00: Their job is to integrate the entire shock phenotype.
- 18:48SPEAKER_00: They have to synthesize the nurse's exam,
- 18:50SPEAKER_00: the RT's ventilator data,
- 18:52SPEAKER_00: the pharmacist's pharmacological warnings,
- 18:55SPEAKER_00: and decide.
- 18:56SPEAKER_00: Does this patient need more vascular squeeze?
- 18:59SPEAKER_00: Do they need a stronger pump?
- 19:01Or do they just need to be rushed to surgery to drain a massive
- 19:05infection?
- 19:06SPEAKER_01: And finally,
- 19:06SPEAKER_01: the perfusionist,
- 19:07who manages things like ECMO machines where the patient's blood
- 19:10is pumped outside
- 19:11SPEAKER_01: their body.
- 19:12The way these drugs interact with plastic tubing is totally
- 19:15different from how they
- 19:16SPEAKER_01: interact with human veins.
- 19:17SPEAKER_00: Exactly.
- 19:18SPEAKER_00: If the team doesn't understand this receptor map together,
- 19:21SPEAKER_00: the only question they ever ask on rounds is,
- 19:23SPEAKER_00: what's the norepinephrine running at?
- 19:25SPEAKER_00: Just checking the knob.
- 19:26SPEAKER_00: Right.
- 19:27SPEAKER_00: If they operate as a symphony, the question transforms.
- 19:30SPEAKER_00: It becomes,
- 19:31what underlying physiology are we actually treating and what
- 19:34harm are we accepting
- 19:35SPEAKER_00: to treat it?
- 19:35SPEAKER_01: What harm are we accepting to treat it?
- 19:37SPEAKER_01: That is such a heavy, profound shift in perspective.
- 19:40It forces you to acknowledge the trade-offs of every single
- 19:44drop of medication.
- 19:45SPEAKER_00: It does.
- 19:45SPEAKER_01: And that brings us to the ultimate mission of this deep dive.
- 19:49SPEAKER_01: The goal isn't to hit a target MAP of 65.
- 19:53SPEAKER_01: The goal is to sustain human life.
- 19:55SPEAKER_01: The receptor map is the bedside map.
- 19:57SPEAKER_00: It truly is.
- 19:58But as we wrap up,
- 19:59I want to leave you with one final provocative thought to chew
- 20:01on.
- 20:02We talked earlier about that 2025 OVISS study where the
- 20:06reinforcement learning AI
- 20:08was actually better than human doctors at knowing the exact
- 20:11mathematical moment to
- 20:12SPEAKER_00: start vasopressin.
- 20:13Yeah,
- 20:13the algorithm saw the biological patterns faster than the
- 20:16humans did.
- 20:16SPEAKER_00: So think about where this is heading.
- 20:18SPEAKER_00: The nurse noticing the patient's skin getting cold?
- 20:42SPEAKER_00: Exactly.
- 20:43Because everything Javier Amador-Castaneda argues in this
- 20:45article tells us that
- 20:47SPEAKER_00: human context,
- 20:48SPEAKER_00: understanding the unquantifiable nuances of a deteriorating body,
- 20:52SPEAKER_00: is the true key to saving a life.
- 20:55Can an algorithm ever be programmed to recognize the difference
- 20:58between a pretty
- 20:58SPEAKER_00: number on a screen and a patient who is quietly slipping away?
- 21:02SPEAKER_01: That is a chilling thought,
- 21:03SPEAKER_01: but an incredibly important one to ponder as technology races forward.
- 21:08SPEAKER_00: Well, that is all the time we have for today.
- 21:10Thank you so much for joining us on this deep dive into the
- 21:12hidden complexities of
- 21:14SPEAKER_00: critical care and vasoactive science.
- 21:16SPEAKER_00: Next time you see a warning light flashing,
- 21:18whether it's on a high-parent medical monitor or just the
- 21:20dashboard of your car,
- 21:22SPEAKER_00: do us all a favor.
- 21:23SPEAKER_00: Don't just treat the light.
- 21:24SPEAKER_00: Look under the hood.
- 21:25SPEAKER_00: Take care, everyone.